CN112578110B - Biological probe and kit for detecting furacilin and furazolidone and application of biological probe and kit - Google Patents
Biological probe and kit for detecting furacilin and furazolidone and application of biological probe and kit Download PDFInfo
- Publication number
- CN112578110B CN112578110B CN202011488124.0A CN202011488124A CN112578110B CN 112578110 B CN112578110 B CN 112578110B CN 202011488124 A CN202011488124 A CN 202011488124A CN 112578110 B CN112578110 B CN 112578110B
- Authority
- CN
- China
- Prior art keywords
- furazolidone
- furacilin
- antibody
- biological probe
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention forms a biological probe by an antibody and a signal carrier loaded with a signal substance. The biological probe of the invention loads a plurality of chromogenic signals, which not only enhances the output degree of the signals, but also has more convenient operation and simpler and easier process compared with the traditional detection system that each detection object corresponds to one detection probe for a plurality of target detection objects. Meanwhile, the dosage of the monoclonal antibody under the same condition can be greatly reduced, and the detection sensitivity of the test strip is improved. After the biological probe and the biological probe are constructed into the immunochromatography test strip, the immunochromatography test strip is applied to simultaneously detecting furacilin and furazolidone in food, the sensitivity of the detected furacilin and furazolidone can reach 1ng/mL, the visual detection line of the derivative of the furacilin metabolite can reach 0.2ng/mL, and the elimination concentration is 3ng/mL; the visual detection line of the furazolidone metabolite derivative can reach 0.4ng/mL, and the elimination concentration is 2.5ng/mL. And the operation is simple and stable, and the components are low.
Description
Technical Field
The invention relates to the technical field of biological detection, in particular to a biological probe for detecting furacilin and furazolidone, a kit and application.
Background
Nitrofurazone and furazolidone, common nitrofuran antibiotics, are rapidly metabolized in vivo, have short half-lives, and cannot exist stably in the form of proto-drugs. Meanwhile, furacilin is metabolized into Semicarbazide (SEM) in vivo, furazolidone is metabolized into 3-amino-2-oxazolone (AOZ) in vivo, both metabolites are tightly bound with proteins in tissues and stably exist in an organism in a bound state, and the longer the residual time is, the stronger the generated toxicity is.
Although various countries prohibit the use of such drugs in the production of non-staple livestock food due to potential carcinogenic and teratogenic side effects of nitrofurazone and furazolidone and their metabolites on humans. However, since nitrofuran antibiotics have killing effect on pathogens such as bacteria, protozoa and the like and fungi and are low in price, the nitrofuran antibiotics are widely applied to livestock and aquatic products for treating and preventing various gastrointestinal infections caused by bacteria and protozoa. Therefore, the method enhances the detection, especially the quick detection, of the antibiotic residues of furacilin and furazolidone in livestock products, aquatic products and feeds so as to know and master the health information of food and feed in time, and is an important link for enhancing the food safety.
Since the furan antibiotics are metabolized in vivo quickly, metabolites SEM and AOZ are taken as standards for analyzing the residual status of the furan antibiotics, and the derivatives NPSEM and CPAOZ are taken as targets for detection if the SEM and AOZ as small molecules cannot generate immune response. At present, the immunochromatography has the characteristics of high specificity, good sensitivity, low component, no pollution, rapid detection and the like, and has a great application prospect. However, because the competitive immunochromatographic strip for detecting furacilin and furazolidone metabolites is subjected to a complex derivatization process and high-quality antibodies, research on the detection of nitrofuran antibiotics by the immunochromatographic strip is still rare.
In recent years, there have been studies to improve detection sensitivity and achieve simultaneous detection of a plurality of targets, which have been conventionally performed by increasing the number of labels to be replaced and preparing different probes for different targets. The immunochromatographic test strip obtained by the method is unstable, and the amount of the monoclonal antibody used is relatively large in order to fully satisfy the coupling of the monoclonal antibody and the material when different probes are prepared, so that the sensitivity of the test strip is reduced, and the cost is increased. Therefore, the multi-target object detection strategy which is simple to operate, sensitive and stable in performance and low in cost is sought, and the immunochromatographic test strip has important significance.
Disclosure of Invention
The invention aims to provide a biological probe for detecting furacilin and furazolidone, a kit and application. The biological probe and the test strip can be used for simultaneously detecting furacilin and furazolidone in food, and have the characteristics of high sensitivity, good specificity, simple operation and good stability.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a biological probe for detecting furacilin and furazolidone, which comprises an antibody and a signal carrier loaded with a signal substance.
Preferably, the antibody is goat anti-mouse immunoglobulin G.
Preferably, the signal substance is nanogold with the particle size of 9-11 nm.
Preferably, the signal carrier is a metal organic framework material MIL-101 taking chromium ions as metal ion centers.
Preferably, the particle size of the signal carrier is 200 to 240nm.
Preferably, the mass ratio of the antibody to the signal carrier carrying the signal substance is 5 to 25 μ g:0.8mg.
The invention also provides an antibody bridge which is prepared from the biological probe, the monoclonal antibody of furacilin and the monoclonal antibody of furazolidone.
Preferably, the mass ratio of the biological probe to the monoclonal antibodies of furacilin and furazolidone is 0.8mg:0 to 1.25. Mu.g: 0 to 2.0 mu g.
The invention also provides a kit for detecting furacilin and furazolidone, which comprises a biological probe or an antibody bridge and a test strip for detecting furacilin and furazolidone.
The invention also provides application of the biological probe in detection of nitrofurazone and furazolidone in food.
The invention also provides application of the kit in detection of furacilin and furazolidone in food.
The invention provides a biological probe and a kit for detecting furacilin and furazolidone and application thereof. Compared with the prior art, its advantage lies in with positive effect:
(1) The sensitivity is high: according to the invention, a signal object is loaded by adopting a metal organic framework material, so that a large amount of nano-gold is gathered together, and a clearer red strip is formed on a detection line, thereby playing a role in amplifying a signal.
(2) The dosage of the antibody is less: the signal enhancement scheme employed in the present invention can significantly reduce the amount of antibody used, further reduction of antibody usage will trigger a more vigorous competition between free analyte and immobilized antigen for the limited antibody binding sites, leading to a more sensitive concentration-response relationship between analyte and signal intensity.
(3) The preparation process is simple and convenient: when the test strip is used for simultaneously detecting multiple detection objects, the trouble of preparing multiple probes corresponding to different detection objects is eliminated, only one biological probe needs to be prepared, and the monoclonal antibody corresponding to the detection objects is mixed in a simple and uniform mixing manner to form an antibody bridge, so that the high-sensitivity field detection of furacilin and furazolidone metabolites can be realized.
Drawings
FIG. 1 is a diagram of the process for preparing an antibody bridge.
FIG. 2 is a structural diagram of the test strip.
Fig. 3 is a view for confirming visible ray and vanishing ray concentration.
FIG. 4 is a specific detection map.
FIG. 5 is a sample sensitivity detection chart.
Detailed Description
The invention provides a biological probe for detecting furacilin and furazolidone, which comprises an antibody and a signal carrier loaded with a signal substance; the antibody is goat anti-mouse immunoglobulin G.
In the invention, the signal substance is nanogold with the particle size of 9-11 nm, and preferably 10nm.
In the invention, the signal carrier is a metal organic framework material MIL-101 taking chromium ions as metal ion centers.
In the present invention, the particle size of the signal carrier is 200 to 240nm, preferably 220nm.
In the invention, the method for loading the signal substance on the signal carrier is a sodium citrate reduction method.
In the present invention, the mass ratio of the antibody to the signal carrier carrying the signal substance is 5 to 25. Mu.g: 0.8mg, preferably 10 to 20. Mu.g: 0.8mg, more preferably 15 μ g:0.8mg.
The invention also provides an antibody bridge which is prepared from the biological probe, the monoclonal antibody of furacilin and the monoclonal antibody of furazolidone.
In the present invention, the monoclonal antibody and the anti-monoclonal antibody against furazolidone are preferably those prepared according to the method of Production of monoclonal antibodies against microorganisms using a modified two-step screening procedure, such as Zhang Daohong et al.
In the invention, the mass ratio of the biological probe to the monoclonal antibodies of furacilin and furazolidone is 0.8mg:0 to 1.25. Mu.g: 0 to 2.0. Mu.g, preferably 0.8mg:0.25 to 1 μ g:0.5 to 1.5. Mu.g, more preferably 0.8mg: 0.6. Mu.g: 1 μ g.
The invention also provides a kit for detecting furacilin and furazolidone, which comprises a biological probe or an antibody bridge and a test strip for detecting furacilin and furazolidone.
In the invention, the working principle of the test strip is as follows: and mixing the sample solution and the prepared antibody bridge, adding the mixture to a sample pad at the lower end of the test strip, and allowing the mixed solution to move towards the water absorption pad along the test strip under the action of capillary. When the sample contains the target object, the target object is combined with the prepared biological probe and electrophoresed upwards together, when the sample reaches a detection line fixed with the antigen, the fixed antigen competes with the target object for limited antigen binding sites on antibodies in the biological probe, the higher the content of nitrofural and furazolidone metabolites in the sample is, the fewer biological probes capable of being combined by the fixed antigen on the detection line are, and the lighter the color of the formed color development zone is. When the immobilized antigen binds to less than a certain number of biological probes, no red line will appear at the detection line. Whether the sample contains furacilin and furazolidone or not, the biological probe which is not intercepted by the detection line or the conjugate of the biological probe and the object to be detected continuously moves to the water absorption pad, so that the sample contains three red strips when not containing furacilin and furazolidone (negative), and contains a certain amount of furacilin and furazolidone (positive), namely a quality control strip, and the comparison shows that the sample contains a light red strip or does not contain the red strip.
The invention also provides application of the biological probe in detection of furacilin and furazolidone in food.
The invention also provides application of the kit in detection of furacilin and furazolidone in food.
The preparation method of the solution used in the examples of the present invention was:
the 0.1mol/L potassium carbonate solution is prepared by the following steps: dissolving 13.8g of potassium carbonate in pure water to fix the volume to 1000mL, and filtering by using a 0.22 mu m filter membrane;
the 1mg/mL furazolidone monoclonal antibody solution is as follows: 1mg of furazolidone monoclonal antibody is dissolved in 1mL of pure water to prepare the furazolidone monoclonal antibody;
the 10% bovine serum albumin solution is: 10g of bovine serum albumin is dissolved in 100mL of pure water and filtered by a 0.22 mu m filter membrane;
the marking washing preservation solution comprises: 2.0g of polyethylene glycol-20000, 0.2g of sodium azide, 0.1235g of boric acid and pure water with constant volume of 1000mL, and is obtained by filtering with a 0.22-micron filter membrane;
the confining liquid A is as follows: 2g of bovine serum albumin, 1g of polyvinylpyrrolidone, 0.02g of sodium azide, 0.8g of sodium chloride, 0.29g of disodium hydrogen phosphate dodecahydrate, 0.02g of potassium chloride and 0.02g of potassium dihydrogen phosphate, and adding water to the mixture to make the volume of the mixture constant to 100 mL.
In the present example, the furacilin standard solution was prepared from NPSEM antigen purchased from Yuanye biology company;
the original concentrations of the furacilin NPSEM antigen are as follows: 100ng/mL;
the furazolidone standard solution is prepared from CPAOZ antigen purchased from Anti Biotechnology (Wuhan. China);
the original concentrations of the furazolidone CPAOZ antigen were: 100ng/mL.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
EXAMPLE 1 preparation of bioprobes and antibody bridges
Preparing a metal organic framework material MIL-101 (Cr) loaded with nano gold: 266.5mg of chlorine hexahydrateDissolving chromium and 166.1mg terephthalic acid in 7.2mL water, stirring at room temperature for 3min, transferring to a reaction kettle with a liner of tetrafluoroethylene, and heating at 210 ℃ for 24h. After returning to room temperature, the recrystallized terephthalic acid was removed by centrifugation at 5000rpm for 3min and washed 3 times with DMF. Taking 10mg of metal organic framework material MIL-101 with the particle size of 220nm to be put into 30mL of water, and adding 200 mu L of HAuCl with the mass fraction of 1% and the particle size of 10nm 4 Stirring at 45 deg.C for 2.5h, heating and stirring to boil, adding 147 μ L trisodium citrate solution, and heating under boiling and stirring for 30min. The solution was cooled at room temperature, washed 3 times with distilled water, and placed in a refrigerator at 4 ℃ for use.
Preparation of biological probes: dissolving 0.8mg of MIL-101 (Cr) powder loaded with nano-gold in deionized water, and adjusting the pH value of the solution to 8.5 by using 0.1mol/L potassium carbonate solution; slowly adding 3 mu L of 5mg/mL sheep anti-mouse immunoglobulin G solution under stirring, and continuously stirring for 1.5h; adding 10% bovine serum albumin solution until the final concentration is 1%, and continuously stirring for 1h; centrifuging at 10,000r/min for 10min, discarding supernatant, adding 100 μ L of labeled washing and preserving solution, and placing in a refrigerator at 4 deg.C for use.
Preparation of antibody bridge: 100 mu L of biological probe solution is measured, 1 mu L of NPSEM monoclonal antibody and 1.5 mu L of CPAOZ monoclonal antibody are added, mixed evenly and placed in a refrigerator at 4 ℃ for standby.
The process for preparing antibody bridges is illustrated in FIG. 1.
Example 2 preparation of test strip for detecting Furacilin and Furazolidone
The device is provided with a lining plate, a water absorption pad, a nitrocellulose membrane and a sample pad are sequentially attached to the lining plate from top to bottom, wherein a quality control line is transversely arranged on the nitrocellulose membrane, a detection line 1 and a detection line 2 are arranged, the detection line 1 is coated with furacilin metabolite-bovine serum albumin conjugate (CPSEM-BSA), and the detection line 2 is coated with furazolidone metabolite-bovine serum albumin conjugate (CPAOZ-BSA). The structure of the test strip is shown in FIG. 2.
The preparation process of the test strip is as follows:
(1) Preparation of absorbent pad
Cutting the absorbent paper into pieces with the length of 18mm and the width of 3mm to obtain the absorbent pad.
(2) Preparation of nitrocellulose membranes
Coating of quality control line:
preparing a solution of 3mg/mL by using sheep anti-mouse immunoglobulin G; it was coated laterally at a coating amount of 0.5. Mu.L/cm by streaking at a position 90mm from the nitrocellulose membrane, and then dried at 37 ℃ for 15min.
Coating of detection line 1:
preparing a conjugate (CPSEM-BSA) of a furacilin metabolite derivative CPSEM-bovine serum albumin into a solution of 0.15 mg/mL; it was coated laterally at a coating amount of 0.4. Mu.L/cm at a position 60mm from the nitrocellulose membrane by streaking, and then dried at 37 ℃ for 15min.
Coating of detection line 2:
preparing a conjugate of furazolidone metabolite derivative CPAOZ-bovine serum albumin (CPAOZ-BSA) into a solution of 0.3 mg/mL; it was coated laterally at a coating amount of 0.4. Mu.L/cm at a position 30mm from the nitrocellulose membrane by streaking, and then dried at 37 ℃ for 15min.
(3) Preparation of sample pad: cutting the glass fiber membrane into pieces with the length of 8mm and the width of 3mm, soaking the glass fiber membrane in the sealing liquid A, drying the glass fiber membrane for 10 to 16 hours at 37 ℃ to obtain a sample pad, and then placing the sample pad in a dryer for storage at room temperature.
(4) Assembling the test strip: firstly, attaching the nitrocellulose membrane to a lining plate, then pressing the nitrocellulose membrane by a sample pad for 1-3 mm, and sequentially attaching the nitrocellulose membrane by a water absorption pad for 1-3 mm to the lining plate to obtain the immunochromatography test strip for detecting furacilin and furazolidone metabolites, which is shown in figure 2.
Example 3 visual and vanishing concentration determination and specificity detection
The test strip prepared in the embodiment 2 and the antibody bridge prepared in the embodiment 1 are used for detecting furacilin and furazolidone standard solutions, the standard solutions are prepared into standard solutions with the intermediate concentration of 10ng/mL by PBS, and then the PBS solution is adopted to dilute the standard solutions with the intermediate concentration of furacilin to 0.2,0.4,0.6,0.8,1.0,1.5,2.0,2.5,3.0 and 3.5ng/mL; the standard solution with furazolidone intermediate concentration of 10ng/mL is diluted to 0.2,0.4,0.6,0.8,1.0,1.5,2.0,2.5,3.0,3.5ng/mL with PBS solution. The concentration of 0ng/mL was replaced with PBS solution. A series of standard solutions were mixed well with 8mg/mL, 4. Mu.L of antibody bridge to obtain sample solutions of different solubilities. The sample pad end of the test strip obtained in example 2 was inserted into sample solutions of different concentrations, and the results were observed after 10min of reaction. The results of the experiment are shown in FIG. 3.
PBS solution is used as a negative control, 5ng/mL CPAOZ diluted by PBS and 5ng/mL MLPSEM are used as positive controls, and 20ng/mL streptomycin, dopamine, estradiol, salbutamol, clenbuterol and ractopamine are detected by the test strip prepared in example 2 and the antibody bridge prepared in example 1 respectively. The results of the experiment are shown in FIG. 4.
FIG. 3 shows: when the standard solution is 0ng/mL, the quality control line, the detection line 1 and the detection line 2 both have obvious red bands, and when the derivative concentration of the furazolidone metabolite is 3ng/mL, the quality control line has a clear red band, the detection line does not exist, the derivative concentration of the furazolidone metabolite is 2.5ng/mL, the quality control line has a clear red band, and the detection line does not exist, which indicates that the linear concentration of the derivative of the furazolidone metabolite is 3ng/mL, and the linear concentration of the derivative of the furazolidone metabolite is 2.5ng/mL.
For the detection of furacilin, the visual detection line can reach 0.2ng/mL, the detection of furazolidone can reach 0.4ng/mL.
FIG. 4 shows: the test strip detects streptomycin, dopamine, estradiol, salbutamol, clenbuterol and ractopamine which do not contain furacilin and furazolidone, and the obtained result is consistent with the result of negative control.
EXAMPLE 4 sample sensitivity detection
A1 g shrimp sample was weighed into a 10mL centrifuge tube and dissolved with 2mL ultrapure water. Then 0.2,0.4, 0.8,1.0, 1.2, 1.4ng/mL of the furazolidone metabolite standard solution is added to the sample respectively, and the mixture is mixed by vortex at room temperature. Then, 200. Mu.L of dimethylsulfoxide dissolved with p-carboxybenzaldehyde (0.05M) was added to the mixture, and each sample was incubated at 37 ℃ for 16h. The derivatized sample was then centrifuged at 10,000rpm for 10min at 4 ℃ and the supernatant collected. Then 0.2,0.4, 0.8,1.0, 1.2, 1.4ng/mL of furacilin metabolite standard solution is added to the sample, and the mixture is mixed by vortex at room temperature. Then, 50. Mu.L of dimethyl sulfoxide dissolved with 2-aminobenzaldehyde (0.04M) and 250. Mu.L of 1M hydrochloric acid were added to the samples, and each sample was incubated at 37 ℃ for 16 hours. The derivatized sample was then centrifuged at 10,000rpm for 10min at 4 ℃ and the supernatant collected. Finally, two supernatants 1:1 after mixing, the antibody bridge of example 1 was added in the following amounts: 8mg/mL, 4. Mu.L. And (3) taking 100 mu L of sample solution as detection liquid, placing the detection liquid in a centrifuge tube, inserting one end of a sample pad of the test strip into the centrifuge tube, taking 100 mu L of shrimp sample without furacilin and furazolidone metabolites as negative control liquid, and reading the result after 10 min. The results are shown in FIG. 5.
The detection line of the detection test strip is not colored or is lighter in color than the detection line of the control test strip, and the detection line is judged to be positive, and the detection line is judged to be negative when the color of the detection line is consistent with the color of the control test strip.
The result of FIG. 5 shows that the detection sensitivity of the test strip to SEM and AOZ can reach 1ng/mL.
The embodiments of the invention provide a biological probe for detecting furacilin and furazolidone, a kit and application thereof. Compared with the prior art, its advantage lies in with positive effect:
(1) The sensitivity is high: the novel metal organic framework material is adopted to load the signal substance, so that a large amount of nano-gold is gathered together, a clearer red strip is formed on the detection line, the signal amplification effect is achieved, and the sensitivity can reach 1ng/mL.
(2) The dosage of the antibody is less: the signal enhancement scheme employed in the present invention can significantly reduce the amount of antibody used, further reduction of antibody usage will trigger a more vigorous competition between free analyte and immobilized antigen for the limited antibody binding sites, thus leading to a more sensitive concentration-reaction relationship between analyte and signal intensity.
(3) The preparation process is simple and convenient: when the test strip is applied to simultaneously detect multiple detection objects, the trouble of preparing multiple probes corresponding to different detection objects is eliminated, only one biological probe needs to be prepared, and the monoclonal antibody corresponding to the detection objects is mixed in a simple and uniform mixing mode to form an antibody bridge, so that the high-sensitivity on-site detection of furacilin and furazolidone metabolites can be realized.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and amendments can be made without departing from the principle of the present invention, and these modifications and amendments should also be considered as the protection scope of the present invention.
Claims (6)
1. A biological probe for detecting furacilin and furazolidone is characterized by comprising an antibody and a signal carrier loaded with a signal substance; the antibody is goat anti-mouse immunoglobulin G;
the signal substance is nano gold with the grain diameter of 9-11 nm;
the signal carrier is a metal organic framework material MIL-101 taking chromium ions as metal ion centers;
the particle size of the signal carrier is 200-240 nm;
the mass ratio of the antibody to the signal carrier loaded with the signal substance is 5-25 mug: 0.8mg.
2. An antibody bridge prepared from the biological probe of claim 1, a monoclonal antibody of nitrofurazone and a monoclonal antibody of furazolidone.
3. The antibody bridge according to claim 2, wherein the mass ratio of the biological probes to the monoclonal antibodies to furacilin and furazolidone is 0.8mg:0 to 1.25. Mu.g: 0 to 2.0 mu g.
4. A kit for detecting furacilin and furazolidone, comprising the biological probe of claim 1 or the antibody bridge of claim 2 or 3 and a test strip for detecting furacilin and furazolidone.
5. Use of the biological probe of claim 1 for detecting nitrofurazone and furazolidone in a food product.
6. Use of the kit of claim 4 for detecting furacilin and furazolidone in a food product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011488124.0A CN112578110B (en) | 2020-12-16 | 2020-12-16 | Biological probe and kit for detecting furacilin and furazolidone and application of biological probe and kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011488124.0A CN112578110B (en) | 2020-12-16 | 2020-12-16 | Biological probe and kit for detecting furacilin and furazolidone and application of biological probe and kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112578110A CN112578110A (en) | 2021-03-30 |
| CN112578110B true CN112578110B (en) | 2023-03-14 |
Family
ID=75135505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011488124.0A Active CN112578110B (en) | 2020-12-16 | 2020-12-16 | Biological probe and kit for detecting furacilin and furazolidone and application of biological probe and kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112578110B (en) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101013129B (en) * | 2007-02-13 | 2011-08-17 | 北京望尔生物技术有限公司 | Enzyme linked immunosorbent reagent casing for detecting furacilin metabolite and uses thereof |
| CN201130183Y (en) * | 2007-08-02 | 2008-10-08 | 北京望尔生物技术有限公司 | Kit for testing ELISA of furanzolidon metabolite |
| CN101349695A (en) * | 2008-08-25 | 2009-01-21 | 深圳市绿诗源生物技术有限公司 | Furacillin metabolite SEM fast detecting reagent kit and uses thereof |
| CN102183634A (en) * | 2011-03-04 | 2011-09-14 | 河北省兽药监察所 | Immune nano gold test strip for quickly detecting four nitrofuran medicaments |
| CN102759622A (en) * | 2011-04-28 | 2012-10-31 | 宝瑞源生物技术(北京)有限公司 | Nitrofurans drug metabolite assay kit and production method thereof |
| CN103288962B (en) * | 2012-02-29 | 2014-12-17 | 华中农业大学 | Monoclonal antibody of furacilin residue marker semicarbazide, and preparation method and application thereof |
| CN202720229U (en) * | 2012-04-07 | 2013-02-06 | 北京勤邦生物技术有限公司 | Kit for detecting furacilin metabolite |
| WO2017147186A1 (en) * | 2016-02-22 | 2017-08-31 | Ursure, Inc. | System and method for detecting therapeutic agents to monitor adherence to a treatment regimen |
| CN106053787A (en) * | 2016-06-06 | 2016-10-26 | 上海师范大学 | Fluorescent immunochromatography test strip for detecting furazolidone metabolites as well as preparation and application |
| CN106380520B (en) * | 2016-10-21 | 2019-07-12 | 河北省科学院生物研究所 | A kind of anti-Furaxone metabolite monoclonal antibody and its application |
| US10500576B2 (en) * | 2017-05-04 | 2019-12-10 | Exxonmobil Research And Engineering Company | Metal organic frameworks, their synthesis and use |
| CN107515299A (en) * | 2017-07-07 | 2017-12-26 | 西北农林科技大学 | A kind of bioprobe, the test strips for detecting furazolidone and its application |
| CN107732255A (en) * | 2017-09-06 | 2018-02-23 | 福建农林大学 | A kind of combination electrode of graphene-containing and metal organic frame and preparation method thereof |
-
2020
- 2020-12-16 CN CN202011488124.0A patent/CN112578110B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN112578110A (en) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | A multiplex immunochromatographic test using gold nanoparticles for the rapid and simultaneous detection of four nitrofuran metabolites in fish samples | |
| Li et al. | Three lateral flow immunochromatographic assays based on different nanoparticle probes for on-site detection of tylosin and tilmicosin in milk and pork | |
| Krska et al. | Analysis of Fusarium toxins in feed | |
| Wang et al. | Novel fabrication of immunochromatographic assay based on up conversion phosphors for sensitive detection of clenbuterol | |
| Dou et al. | Chemical-staining based lateral flow immunoassay: A nanomaterials-free and ultra-simple tool for a small molecule detection | |
| Li et al. | Determination of veterinary drug residues in food of animal origin: Sample preparation methods and analytical techniques | |
| CN105784990A (en) | Test strip for detecting aflatoxin B1 or M1 by utilizing aptamer | |
| CN110987882B (en) | Fluorescence-quenched colloidal gold immunochromatographic test strip, preparation method and application thereof | |
| CN112904007B (en) | Method for detecting vomitoxin based on blue magnetic porous double-nanoenzyme/quantum dot double-signal amplification immunochromatographic test strip | |
| Huang et al. | An enzyme-free biosensor for sensitive detection of Salmonella using curcumin as signal reporter and click chemistry for signal amplification | |
| CN114594262B (en) | Mycotoxin magnetic chemiluminescence immunoassay kit based on bifunctional fusion protein and application thereof | |
| Li et al. | An ultrasensitive competitive immunochromatographic assay (ICA) based on surface-enhanced Raman scattering (SERS) for direct detection of 3-amino-5-methylmorpholino-2-oxazolidinone (AMOZ) in tissue and urine samples | |
| Xu et al. | Functional up-conversion nanoparticle-based immunochromatography assay for simultaneous and sensitive detection of residues of four tetracycline antibiotics in milk | |
| Tang et al. | A sensitive immunochromatographic assay using colloidal gold–antibody probe for the rapid detection of semicarbazide in meat specimens | |
| CN111505284A (en) | Test paper strip and sensor for detecting novel coronavirus SARS-CoV-2, preparation and application thereof | |
| Li et al. | An immunochromatographic assay for rapid and direct detection of 3‐amino‐5‐morpholino‐2‐oxazolidone (AMOZ) in meat and feed samples | |
| KR101451733B1 (en) | Labeling agent for aflatoxin B1 detection and the kit for detecting aflatoxin B1 comprising thereof | |
| Peng et al. | Fluorescence nanobiosensor for simultaneous detection of multiple veterinary drugs in chicken samples | |
| Wang et al. | Multiplex immunochromatographic platform based on crystal violet tag for simultaneous detection of streptomycin and chloramphenicol | |
| Pan et al. | Comparison of two fluorescence quantitative immunochromatographic assays for the detection of amantadine in chicken muscle | |
| CN112578110B (en) | Biological probe and kit for detecting furacilin and furazolidone and application of biological probe and kit | |
| CN112903649B (en) | Double-excitation orthogonal emission up-conversion luminescence nanoparticle, multi-flux detection immunochromatography test paper and application thereof | |
| Chen et al. | Well-oriented immobilized immunoaffinity magnetic beads for detection of fumonisins in grains and feeds via pre-column automatic derivatization of high-performance liquid chromatography | |
| Xie et al. | Rapid determination of nosiheptide in feed based on dispersive SPE coupled with HPLC | |
| CN108241061B (en) | Vomitoxin detection colloidal gold rapid detection card and kit, and method for detecting vomitoxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |